secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2024-12-03T23:59:59+00:00
Accession:  0001664710-24-000097
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros licenses elritercept to Takeda for $200M upfront; milestones up to $1.1B
------------------------------------------------------------------------------

- Upfront payment of $200M; eligible for up to $370M in development/commercial milestones and $740M in sales milestones.
- Tiered royalties on net sales in Territory (ex-China) from low double-digits to high teens, subject to reductions.
- Elritercept in Phase 2 for MDS and myelofibrosis; Phase 3 RENEW trial for MDS to begin enrollment soon.
- Keros expects upfront proceeds to extend cash runway into Q4 2028, supporting cibotercept and KER-065 programs.
- Agreement effective subject to HSR Act clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000097/0001664710-24-000097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471024000097/kros-20241203.htm
  HTML page:      https://secwatch.observer/filing/0001664710-24-000097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer